Atossa TherapeuticsATOS
ATOS
About: Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Employees: 13
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
59% more call options, than puts
Call options by funds: $165K | Put options by funds: $104K
32% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 22
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
2.05% more ownership
Funds ownership: 21.74% [Q3] → 23.79% (+2.05%) [Q4]
0% more funds holding
Funds holding: 86 [Q3] → 86 (+0) [Q4]
32% less capital invested
Capital invested by funds: $41.6M [Q3] → $28.3M (-$13.3M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
680%
upside
Avg. target
$7.13
694%
upside
High target
$7.25
707%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo 47% 1-year accuracy 41 / 87 met price target | 707%upside $7.25 | Buy Maintained | 21 Apr 2025 |
HC Wainwright & Co. Emily Bodnar 21% 1-year accuracy 33 / 160 met price target | 680%upside $7 | Buy Reiterated | 26 Mar 2025 |
Financial journalist opinion
Based on 4 articles about ATOS published over the past 30 days
Neutral
GlobeNewsWire
8 hours ago
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,281,056) directed to highly pure and stable enteric oral formulations comprising (Z)-endoxifen as well as therapeutic methods of using those oral formulations.
Neutral
GlobeNewsWire
1 day ago
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today outlined a framework for a pioneering Phase 3 clinical study titled SMART 2.0. The proposed trial would investigate the potential of oral (Z)-endoxifen, a potent Selective Estrogen Receptor Modulator (SERM) for estrogen receptor inhibition, to significantly reduce interval breast cancer in women identified as high-risk through advanced mammographic screening techniques. The proposed SMART 2.0 study was presented at the American Association for Cancer Research (AACR) Annual Meeting and represents a future research program and potential partnership opportunity to advance this critical initiative for women at high risk of breast cancer.
Neutral
GlobeNewsWire
1 week ago
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,275,684) directed to enteric oral formulations comprising (Z)-endoxifen as well as methods of treating subjects with those oral formulations.
Neutral
PRNewsWire
2 weeks ago
Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer
CAMBRIDGE, Mass. , April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS).
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy
Atossa Genetics (ATOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Seeking Alpha
1 month ago
Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript
Atossa Therapeutics, Inc. (NASDAQ:ATOS ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Michael Parks - VP of Investor and Public Relations Steven Quay - President and CEO Heather Rees - CFO Conference Call Participants Emily Bodnar - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good morning, everyone, and welcome to the Atossa Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call.
Neutral
GlobeNewsWire
1 month ago
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments.
Neutral
GlobeNewsWire
1 month ago
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time
Neutral
GlobeNewsWire
1 month ago
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced its strategic decision to pursue a metastatic breast cancer indication for (Z)-endoxifen. Atossa believes that pursuing a metastatic indication may offer a more efficient regulatory pathway to deliver (Z)-endoxifen to women in urgent need, and simultaneously plans to work with the FDA to advance additional indications, such as breast cancer prevention and neoadjuvant therapy, that often require larger and longer clinical trials.
Neutral
GlobeNewsWire
2 months ago
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere congratulations to Dr. Tessa Cigler, esteemed Board Director at Atossa and Associate Professor of Clinical Medicine at Weill Cornell Medicine, and the Weill Cornell Medicine team for being awarded a five-year, $2.3 million grant from the Centers for Disease Control and Prevention (CDC). This grant will fund initiatives aimed at improving equitable access to care, quality of life, and survival outcomes for young breast cancer patients across New York City.
Charts implemented using Lightweight Charts™